MedTrace Logo

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

NCT00126672 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-04-25

Study results available
· View outcomes & findings →

Summary

This research study is evaluating a drug called rapamycin as a possible treatment for the lumps (or tumors) that form in the kidneys, called angiomyolipomas, in people who have either TSC or LAM. Kidney angiomyolipomas are tumors that are made up of blood vessels, muscle and fat. Rapamycin has been approved to treat other diseases, but it is investigational for treating kidney angiomyolipomas.

Investigational means that it is being as a possible treatment for kidney angiomyolipomas but is not currently approved by the U.S. Food and Drug Administration (FDA) for treating this disease.

Conditions

  • Nonmalignant Neoplasm
  • Tuberous Sclerosis
  • Lymphangioleimyomatosis
  • Kidney Angiomyolipoma

Interventions

DRUG

Rapamycin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Tuberous Sclerosis Alliance

    collaborator OTHER

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • Sandra Dabora, MD, PhD · Dana-Farber/Brigham and Women's Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-20
Primary Completion
2010-04-30
Completion
2010-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00126672 on ClinicalTrials.gov